Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Avapritinib in the Treatment of Unresectable or Recurrent Metastatic Gastrointestinal Stromal Tumors Non-exon18 Mutations of PDGFRA:A Real-world Study

NCT05461664 is registered in ClinicalTrials.gov with Xinhua Zhang, MD as lead sponsor.

NCT NCT05461664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05461664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic Gastrointestinal Stromal Tumors Non-exon18 Mutations of PDGFRA:A Real-world Study
Lead sponsor
Xinhua Zhang, MD
Phase
Observational
Overall status
Recruiting
Start date
July 10, 2022
Completion date
December 31, 2025
Enrollment
74 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal stromal tumors, recurrent metastatic malignant neoplasm, unresectable solid tumor